Kevin Skol is SVP at Arcturus Therapeutics leading business development and alliance management. Kevin drives new business through strategic relationships with biopharma, oversees the alliances, plans for clinical and commercial success of Arcturus' pipeline and provides strategy for a leading company in the evolving RNA medicines field. Prior to Arcturus, Kevin was VP of Vertical Market Development at a machine learning, AI startup called Eyenuk which provides diabetic retinopathy screening at the point-of-care. Kevin also spent years heading business development at Ionis Pharmaceuticals where his extensive transaction experience resulted in total deal value of over $3.0B. Earlier positions in commercial, marketing or corporate development roles included time at Valeant Pharmaceuticals and Elan Corporation. Kevin was also CBO during the corporate reorganization of Digital Gene Technologies. Kevin earned an MBA at Harvard Business School and is a graduate of Yale University.